CB213 is poised to enter clinical development and, through intercepting both PD1 and LAG3 resistance mechanisms, may benefit patients with tumours escaping front-line immunological control.

almost 3 years ago

Journal

PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)

CB213

over4years

[VIRTUAL] CB213: A half-life extended bispecific Humabody VH delivering dual checkpoint blockade to reverse the dysfunction of LAG3+PD-1+ double-positive T cells (AACR-II 2020)

Humabody bispecific bound to PD1+LAG3- Jurkat cells with a lower EC50 compared to Nivolumab whereas binding to PD-1-LAG3+ Jurkat cells was equivalent to a benchmark anti-LAG3 mAb. Together these data support preclinical and clinical development of CB213, a novel 2:1 asymmetric Humabody dual checkpoint inhibitor targeting LAG3/PD-1 double positive dysfunctional T cells.

over 4 years ago

Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2)

LAG3 expression

Opdivo (nivolumab) • CB213